Leveraging A Flexible And Efficient Rapid Development Framework™ To Accelerate Development And Manufacturing Of Cell And Gene Therapies

Bringing cell and gene therapies (CGTs) from breakthrough discovery to reliable, large-scale manufacturing is inherently complex. Moving toward commercialization demands proactive risk assessment, well-defined and repeatable processes, and strong, qualification-ready analytical methods established early in development. Although conventional platform strategies can shorten timelines, they often depend on fixed process designs that may limit flexibility and lock developers into less-than-ideal solutions.

To help overcome these constraints, Thermo Fisher Scientific introduced the Rapid Development Framework™, a structured yet adaptable model created to streamline regenerative medicine and immunotherapy development. Drawing on more than two decades of expertise in advanced therapies, this comprehensive approach integrates process development with analytical strategy to speed progress from early research through manufacturing — while remaining customizable to the unique requirements of each program.

In the webinar highlighted below, we examine practical case studies showcasing how the Rapid Development Framework™ supports viral vector, CAR-T, and iPSC workflows, alongside aligned analytical solutions. The session also explores how CDMO partnerships can further accelerate timelines and demonstrates how this methodology improves consistency, lowers development risk, strengthens product quality, and enhances patient safety — illustrated with real-world examples of measurable time and cost efficiencies.